D-Cl-amidine | 1404060-15-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: D-Cl-amidine
• 英文别名: N-[(2R)-1-amino-5-[(1-amino-2-chloroethylidene)amino]-1-oxopentan-2-yl]benzamide
• CAS: 1404060-15-6
• 化学式: C₁₄H₁₉ClN₄O₂
• 分子量: 310.783
• InChiKey: BPWATVWOHQZVRP-LLVKDONJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  21
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  111
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  在 ammonium hydroxide 、 三乙胺 、 三氟乙酸 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 19.17h， 生成 D-Cl-amidine
  参考文献：
  名称：

  d-Amino Acid-Based Protein Arginine Deiminase Inhibitors: Synthesis, Pharmacokinetics, and in Cellulo Efficacy

  摘要：

  The protein arginine deiminases (PADs) are known to play a crucial role in the onset and progression of multiple inflammatory diseases, including rheumatoid arthritis, inflammatory bowel disease, and cancer. However, it is not known how each of the five PAD isozymes contributes to disease pathogenesis. As such, potent, selective, and bioavailable PAD inhibitors will be useful chemical probes to elucidate the specific roles of each isozyme. Because D-amino amino acids often possess enhanced in cellulo stability, and perhaps unique selectivities, we synthesized a series of D-amino acid analogues of our Pan-PAD inhibitor Cl-amicline, hypothesizing that this change would provide inhibitors with enhanced pharmacokinetic properties. Herein, we demonstrate that D-Cl-amidine and D-o-F-amidine are potent and highly selective inhibitors of PAD1. The pharmacokinetic properties of D-Cl-amidine were moderately improved over those of L-Cl-amidine, and this compound exhibited similar cell killing in a PAD1 expressing, triple-negative MDA-MB-231 breast cancer cell line. These inhibitors represent an important step in our efforts to develop stable, bioavailable, and highly selective inhibitors for all of the PAD isozymes.

  DOI：

  10.1021/ml300288d

文献信息

• Citrullinated proteins: a post-translated modification of myocardial proteins as marker of physiological and pathological disease
  申请人：Cedars-Sinai Medical Center

  公开号：US10309974B2

  公开（公告）日：2019-06-04

  Disclosed herein are methods for diagnosing cardiovascular disease. The methods comprise detection of citrullinated proteins and/or citrullinated peptides. Also disclosed herein are methods, compositions, and kits for diagnosing and/or treating cardiovascular disease.

  本文公开了诊断心血管疾病的方法。这些方法包括检测瓜氨酸化蛋白质和/或瓜氨酸化肽。本文还公开了诊断和/或治疗心血管疾病的方法、组合物和试剂盒。
• Methods for improved endovascular thrombectomy using 3,3′-diindolylmethane
  申请人：Boulder BioScience LLC

  公开号：US11529331B2

  公开（公告）日：2022-12-20

  Provided herein are methods of enhancing mechanical thrombectomy during endovascular therapy for acute thrombosis using 3,3′-diindolylmethane.

  本文提供了在急性血栓形成的血管内治疗中使用 3,3′-二吲哚甲烷加强机械血栓切除的方法。
• COMPOSITIONS AND METHODS FOR INHIBITING INFLAMMATION
  申请人：The University of Memphis Research Foundation

  公开号：EP3761971A1

  公开（公告）日：2021-01-13
• CITRULLINATED PROTEINS: A POST-TRANSLATED MODIFICATION OF MYOCARDIAL PROTEINS AS MARKER OF PHYSIOLOGICAL AND PATHOLOGICAL DISEASE
  申请人：Cedars-Sinai Medical Center

  公开号：US20180136232A1

  公开（公告）日：2018-05-17

  Disclosed herein are methods for diagnosing cardiovascular disease. The methods comprise detection of citrullinated proteins and/or citrullinated peptides. Also disclosed herein are methods, compositions, and kits for diagnosing and/or treating cardiovascular disease.
• METHODS FOR IMPROVED ENDOVASCULAR THROMBECTOMY USING 3,3'-DIINDOLYLMETHANE
  申请人：Boulder BioScience LLC

  公开号：US20220008387A1

  公开（公告）日：2022-01-13

  Provided herein are methods of enhancing mechanical thrombectomy during endovascular therapy for acute thrombosis using 3,3′-diindolylmethane.